会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • 5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one derivatives,
preparation thereof, intermediates thereof and drugs containing the same
    • 5H,10H-咪唑并[1,2-a]茚并[1,2-e]吡嗪-4-酮衍生物,其制备方法,其中间体和含有它们的药物
    • US5990108A
    • 1999-11-23
    • US101428
    • 1998-07-09
    • Jean-Claude AloupJean BouquerelDominique DamourJean-Claude HardyPatrick JimonetFranco ManfreSerge MignaniPatrick Nemecek
    • Jean-Claude AloupJean BouquerelDominique DamourJean-Claude HardyPatrick JimonetFranco ManfreSerge MignaniPatrick Nemecek
    • A61K31/00A61K31/495A61K31/4985A61K31/675A61P1/00A61P1/14A61P25/00A61P29/00A61P43/00C07D233/90C07D235/00C07D487/04C07F9/6561
    • C07D487/04C07F9/6561
    • Compounds of formula (I), wherein R is a hydrogen atom or a --COOH, -alk-COOH, --PO.sub.3 H.sub.2, --CH.sub.2 --PO.sub.3 H.sub.2, or --CH.dbd.CH--COOH radical, or a phenyl radical substituted by a carboxy radical, R.sub.1 is an alk-CN, -alk-COOH, -alk-Het, alk-PO.sub.3 H.sub.2 or -alk-CO--NH--SO.sub.2 R.sub.2 radical, R.sub.2 is an alkyl or phenyl radical, alk is an alkyl radical, Het is a saturated or unsaturated mono- or polycyclic heterocyclic ring containing 1-9 carbon atoms and one or more heteroatoms selected from O, S and N, said heterocyclic ring optionally being substituted by one or more alkyl, phenyl or phenylalkyl radicals, with the proviso that when R is a hydrogen atom or a --COOH or --PO.sub.3 H.sub.2 radical, R.sub.1 cannot be -alk-COOH, isomers, racemic mixtures, enantiomers and diastereoisomers thereof, salts thereof, the preparation thereof, intermediates thereof and drugs containing said compounds, are disclosed. The compounds of formula (I) have valuable pharmacological properties and are antagonists of the .alpha.-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor also known as the quisqualate receptor. Furthermore, the compounds of formula (I) are non-competitive antagonists of the N-methyl-D-aspartate (NMDA) receptor, and specifically ligands for NMDA receptor glycine modulator sites. ##STR1##
    • PCT No.PCT / FR97 / 00019 Sec。 371日期:1998年7月9日 102(e)日期1998年7月9日PCT 1997年1月6日PCT PCT。 出版物WO97 / 25328 日期:1997年7月17日式(I)化合物其中R为氢原子或-COOH,-alk-COOH,-PO3H2,-CH2-PO3H2或-CH = CH-COOH基,或苯基取代 通过羧基,R 1是烷基-C CN,-alk-COOH,-alk-Het,alk-PO 3 H 2或-alk -CO-NH-SO 2 R 2基团,R 2是烷基或苯基, Het是含有1-9个碳原子和一个或多个选自O,S和N的杂原子的饱和或不饱和单环或多环杂环,所述杂环任选被一个或多个烷基,苯基或苯基烷基取代,其中 条件是当R是氢原子或-COOH或-PO 3 H 2基团时,R 1不能是-alk COOH,其异构体,外消旋混合物,对映异构体和非对映异构体,其盐,其制备,其中间体和含有所述化合物的药物, 被披露。 式(I)化合物具有有价值的药理学性质,也是也称为quisqualate受体的α-氨基-3-羟基-5-甲基-4-异恶唑丙酸(AMPA)受体的拮抗剂。 此外,式(I)化合物是N-甲基-D-天冬氨酸(NMDA)受体的非竞争性拮抗剂,特别是NMDA受体甘氨酸调节剂位点的配体。
    • 10. 发明授权
    • Benzopyran derivatives, their preparation and pharmaceutical
compositions containing them
    • 苯并吡喃衍生物,其制备方法和含有它们的药物组合物
    • US5025013A
    • 1991-06-18
    • US465330
    • 1990-01-16
    • Michel BarreauJean-Claude HardyJean-Paul MartinChristian Renault
    • Michel BarreauJean-Claude HardyJean-Paul MartinChristian Renault
    • A61K31/35A61K31/352A61K31/40A61K31/44A61K31/443A61K31/445A61K31/47A61K31/495A61P9/06C07D311/58C07D311/70C07D405/06C07D405/12C07D405/14
    • C07D405/06C07D311/58C07D405/12C07D405/14
    • New benzopyran derivatives of general formula (I) in which:R.sub.1 represents a hydrogen or halogen atom or a hydroxy, alkyloxy, nitro, amino, alkylsulphonamido or acylamino radical,R represents(1) radical ##STR1## R.sub.2 and R.sub.3, which may be identical or different, being H, halogen, OH, alkyl, alkyloxy, NH.sub.2, alkylsulphonamido or NO.sub.2, or(2) a radical ##STR2## n being 0 or 1, R.sub.4 being H, alkyl or optionally substituted phenyl and Q is acyl, alkylsulphonyl or ##STR3## Y being --CO-- or --SO.sub.2 -- and Z being a single bond, --CH.sub.2 -- or --NH--, or(3) a radical ##STR4## n being 0 or 1, m being 0 or 2, X being C or N (if n=0), W being a bond or --NH-- and AR being pyridyl, indolyl, quinolyl, 2-alkylquinolyl or phenyl optionally substituted with R.sub.2 and R.sub.3, provided that n=0 when X equals N, or(4) a radical of general formula: ##STR5## R.sub.7 being H or alkyl, or alternatively (5) a radical ##STR6## R' and R" are identical and represent hydrogen atoms or alkyl radicals, their isomeric forms and the mixtures thereof, and their addition salts with acids.These new products are useful as anti-arrhythmic and antifibrillating agents. ##STR7##
    • 新的通式(I)的苯并吡喃衍生物,其中:R 1表示氢或卤素原子或羟基,烷氧基,硝基,氨基,烷基磺酰胺基或酰基氨基,R表示(1)基团R 2和R 3,其可以是 相同或不同的是H,卤素,OH,烷基,烷氧基,NH 2,烷基磺酰胺基或NO 2,或(2)基团n为0或1,R 4为H,烷基或任选取代的苯基,Q为酰基, 烷基磺酰基或Y为-CO-或-SO 2 - ,Z为单键,-CH 2 - 或-NH-,或(3)基团n为0或1,m为0或2, X是C或N(如果n = 0),W是键或-NH-,并且AR是吡啶基,吲哚基,喹啉基,2-烷基喹啉基或任选被R 2和R 3取代的苯基,条件是当X等于N时,n = ,或(4)通式如下的基团:R7是H或烷基,或者(5)基团R'和R“相同并代表氢原子或烷基,它们的异构形式和 其混合物, d它们与酸的加成盐。 这些新产品可用作抗心律不齐和抗纤颤剂。 (一)